http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Visible-Light-Induced Arylthiofluoroalkylations of Unactivated Heteroaromatics and Alkenes
Choi, Yeojin,Yu, Chunghyeon,Kim, Jun Soo,Cho, Eun Jin American Chemical Society 2016 ORGANIC LETTERS Vol.18 No.13
<P>Visible-light-induced arylthiofluoroalkylations of unactivated heteroaromatics and alkenes have been developed utilizing readily available arylthiofluoroalkyl sources. This method enables simultaneous installation of sulfur and fluoroalkyl moieties, two important functional groups, which demonstrates its potential use for late-stage modifications in the synthesis of functional molecules. This method can be easily utilized to fine-tune the properties of lead molecules in drug development by controlling the number of fluorine atoms in the reagents.</P>
Synthesis of cyclopenta-fused polycyclic aromatic hydrocarbons utilizing aryl-substituted anilines
Choi, Yeojin,Chatterjee, Tanmay,Kim, Jun,Kim, Jun Soo,Cho, Eun Jin The Royal Society of Chemistry 2016 Organic & Biomolecular Chemistry Vol.14 No.28
<P>Cyclopenta-fused polycyclic aromatic hydrocarbons (CP-PAHs), potentially electronically and biologically highly active materials, were synthesized from readily available 2-aryl-substituted anilines. Reactions occur under extremely mild, room temperature conditions using (BuONO)-Bu-t as the sole reagent. The use of a nitrite source generates a reactive diazonium intermediate in situ that then reacts with a tethered polycyclic aromatic moiety by intramolecular aromatic substitution. This protocol could be presented as one of the simplest methods to access CP-PAHs.</P>
Yeojin Bang,임주희,Hyun Jin Choi 대한약학회 2021 Archives of Pharmacal Research Vol.44 No.6
Parkinson’s disease (PD) is a progressive neurodegenerativedisease characterized by movement dysfunctiondue to selective degeneration of dopaminergic neuronsin the substantia nigra pars compacta. Non-motor symptomsof PD (e.g., sensory dysfunction, sleep disturbance, constipation,neuropsychiatric symptoms) precede motor symptoms,appear at all stages, and impact the quality of life,but they frequently go unrecognized and remain untreated. Even when identifi ed, traditional dopamine replacementtherapies have little eff ect. We discuss here the pathologyof two PD-associated non-motor symptoms: olfactory dysfunctionand depression. Olfactory dysfunction is one ofthe earliest non-motor symptoms in PD and predates theonset of motor symptoms. It is accompanied by early depositionof Lewy pathology and neurotransmitter alterations. Because of the correlation between olfactory dysfunctionand an increased risk of progression to PD, olfactory testingcan potentially be a specifi c diagnostic marker of PD in theprodromal stage. Depression is a prevalent PD-associatedsymptom and is often associated with reduced quality oflife. Although the pathophysiology of depression in PD isunclear, studies suggest a causal relationship with abnormalneurotransmission and abnormal adult neurogenesis. Here,we summarize recent progress in the pathology of the nonmotorsymptoms of PD, aiming to provide better guidancefor its eff ective management.
Heat Treatment and TG-DTA Analysis of Uranyl Nitrate and Uranium Oxides
Yeojin Kim,Gun Young Yoon,Gyun Seob Song,Yulim Lee,Jae Hak Cheong,Sangjoon Ahn,Jaeyeong Park,Won Pyo Jeong,Seungyeon Choi,Kwang Heon Park 한국방사성폐기물학회 2023 한국방사성폐기물학회 학술논문요약집 Vol.21 No.2
The solid-state chemistry of uranium is essential to the nuclear fuel cycle. Uranyl nitrate is a key compound that is produced at various stages of the nuclear fuel cycle, both in front-end and backend cycles. It is typically formed by dissolving spent nuclear fuel in nitric acid or through a wet conversion process for the preparation of UF6. Additionally, uranium oxides are a primary consideration in the nuclear fuel cycle because they are the most commonly used nuclear fuel in commercial nuclear reactors. Therefore, it is crucial to understand the oxidation and thermal behavior of uranium oxides and uranyl nitrates. Under the ‘2023 Nuclear Global Researcher Training Program for the Back-end Nuclear Fuel Cycle,’ supported by KONICOF, several experiments were conducted at IMRAM (Institute of Multidisciplinary Research for Advanced Materials) at Tohoku University. First, the recovery ratio of uranium was analyzed during the synthesis of uranyl nitrate by dissolving the actual radioisotope, U3O8, in a nitric acid solution. Second, thermogravimetric-differential thermal analysis (TG-DTA) of uranyl nitrate (UO2(NO3)2) and hyper-stoichiometric uranium dioxide (UO2+X) was performed. The enthalpy change was discussed to confirm the mechanism of thermal decomposition of uranyl nitrate under heating conditions and to determine the chemical hydrate form of uranyl nitrate. In the case of UO2+X, the value of ‘x’ was determined through the calculation of weight change data, and the initial form was verified using the phase diagram for the U-O system. Finally, the formation of a few UO2+X compounds was observed with heat treatment of uranyl nitrate and uranium dioxide at different temperature intervals (450°C-600°C). As a result of these studies, a deeper understanding of the thermal and chemical behavior of uranium compounds was achieved. This knowledge is vital for improving the efficiency and safety of nuclear fuel cycle processes and contributes to advancements in nuclear science and technology.
Yeojin Sung,Seungbin Cha,Sang Bum Kim,Hakhyun Kim,Seonghwi Choi,Sejin Oh,Minseo Kim,Yunji Lee,Gino Kwon,Jooyoung Lee,Joo-Youn Lee,한균희,김현석 생화학분자생물학회 2022 BMB Reports Vol.55 No.12
Epithelial-to-mesenchymal transition (EMT)-subtype gastric cancershave the worst prognosis due to their higher recurrence rate,higher probability of developing metastases and higher chemoresistancecompared to those of other molecular subtypes. Pharmacologicallyactionable somatic mutations are rarely found inEMT-subtype gastric cancers, limiting the utility of targeted therapies. Here, we conducted a high-throughput chemical screenusing 37 gastric cancer cell lines and 48,467 synthetic smallmoleculecompounds. We identified YK-135, a small-moleculecompound that showed higher cytotoxicity toward EMT-subtypegastric cancer cell lines than toward non-EMT-subtype gastriccancer cell lines. YK-135 exerts its cytotoxic effects by inhibitingmitochondrial complex I activity and inducing AMP-activatedprotein kinase (AMPK)-mediated apoptosis. We found that thelower glycolytic capacity of the EMT-subtype gastric cancer cellsconfers synthetic lethality to the inhibition of mitochondrialcomplex I, possibly by failing to maintain energy homeostasis. Other well-known mitochondrial complex I inhibitors (e.g., rotenoneand phenformin) mimic the efficacy of YK-135, supportingour results. These findings highlight mitochondrial complex Iinhibitors as promising therapeutic agents for EMT-subtype gastriccancers and YK-135 as a novel chemical scaffold for further drugdevelopment.